To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch.
The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. It includes a brief description of each study, an assessment of the reporting of some methodological quality features and the main conclusions of the report written by the Centre for Evidence in Transplantation (CET). RCTs and systematic reviews are selected by the Centre for Evidence in Transplantation on the basis of quality or interest. Electronic publications ahead of print are listed as [record in progress].
The first issue of the Transplant Trial Watch was published in September 2009. It is now made available to thousands of transplant professionals worldwide each month.
Click on each trial for more detail of findings and quality.
July 2013
Kidney transplantation
Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial.
Amer H, Griffin MD, et al. American Journal of Transplantation 2013; 13(6):1576-85
Monitoring of CD3(+) T-Cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation.
Ata P, Kara M, et al. Transplantation Proceedings 2013; 45(3): 929-931.
Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte antiglobulin dosing regimens: Results of a randomized trial.
Buchler M, Longuet H, et al. Transplant Immunology 2013; 28(2-3):120-6.
Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients.
Perez, V, Sanchez-Escuredo A, et al. European Journal of Pharmacology 2013; 709(1-3):72-9.
Effect of onversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients.
Riegersperger M, Plischke M, et al. Transplantation 2013;95(11):1338-45.
Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.
Russ GR, Tedesco-Silva H, et al. American Journal of Transplantation 2013; 13(7):1746-56.
The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production.
Smeekens S P, van den Hoogen MW, et al Transplant Immunology 2013; pii: S0966-3274(13)00033-6.
Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients.
Tedesco-Silva H, Kho MM, et al. American Journal of Transplantation 2013; 13(7):1757-68.
Liver transplantation
Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation.
Fayed N, Refaat EK, et al. Journal of Critical Care 2013; pii: S0883-9441(13)00060-9
Completely steroid-free immunosuppression in liver transplantation: a randomized study.
Ramirez CB, Doria C, et al. Clinical Transplantation 2013; 27(3):463-71.